The FDA has granted Impella® its highest level of approval as a safe and effective therapy for high-risk PCI, cardiogenic shock and right heart failure.
Peer-reviewed clinical studies have published on Impella, including the PROTECT II randomized controlled trial
Clinical society guidelines include Impella heart pumps
Patients have been treated with Impella heart pumps
Influential Trials in High-Risk PCI: Shaping the Future of Ischemic Heart Failure Therapy
Jonathan Hill, MD, discusses influential trials in high-risk PCI that are shaping the future of ischemic heart failure therapy.
For Referring Providers
Are you caring for patients with heart disease? Learn more about how Impella heart pumps work, the benefits of Protected PCI with Impella and explore patient identification resources.
- Wollmuth, J., Patel, M. et al. (2022). JSCAI, 100350. https://doi.org/10.1016/j.jscai.2022.100350